About alvotech - ALVO
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
ALVO At a Glance
Alvotech
9, rue de Bitbourg
Luxembourg, Luxembourg 1273
| Phone | 352-422-4500 | Revenue | 489.68M | |
| Industry | Biotechnology | Net Income | -231,864,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 435.558% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,032 | |
| View SEC Filings |
ALVO Valuation
| P/E Current | 25.89 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.239 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 47.476 |
| Enterprise Value to Sales | 9.564 |
| Total Debt to Enterprise Value | 0.254 |
ALVO Efficiency
| Revenue/Employee | 474,498.062 |
| Income Per Employee | -224,674.419 |
| Receivables Turnover | 1.945 |
| Total Asset Turnover | 0.451 |
ALVO Liquidity
| Current Ratio | 2.353 |
| Quick Ratio | 1.692 |
| Cash Ratio | 0.266 |
ALVO Profitability
| Gross Margin | 59.581 |
| Operating Margin | 13.753 |
| Pretax Margin | -44.429 |
| Net Margin | -47.35 |
| Return on Assets | -21.355 |
| Return on Equity | N/A |
| Return on Total Capital | -29.823 |
| Return on Invested Capital | -55.836 |
ALVO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 153.092 |
| Total Debt to Total Assets | 97.449 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 147.662 |